|
|
Nanosys today announced the creation of QD Soleil™, a wholly owned division focused on the use of its proprietary nanotechnology in solar panel cell designs. Nanotechnology is the next step in the natural evolution of a solar generated grid-ready energy supply.
QD Soleil’s intellectual property is a seminal estate that includes over 500 patents and patent applications. This technology has been refined over many years by Nanosys and exploits the best in class inorganic material compositions, processing and integration chemistries, and includes the most stable nanomaterial formulations known. Applications of the technology and intellectual property are broad and include additive enhancement layers for light conversion engineering, nano-particle inks, light waveguide concentrators and nanomaterial composites for enhancing overall solar cell efficiency. Nanosys is considering strategic options to maximize the value of QD Soleil, including possible sale to a large photovoltaic manufacturer. QD Soleil is now meeting with potential partners and parties interested in acquiring a substantial footprint in nanotechnology for photovoltaics.
“Based on the current administration’s energy focus, the U.S. is likely to grow into the largest installed market of solar panels in the world over the next five years,” commented Nanosys CEO Jason Hartlove. “Nanosys is one of the world’s leading nanotechnology companies, with a consolidated position in inorganic nanotechnology, and significant product launches in other areas such as green lighting this year. Therefore, we believe that QD Soleil can focus and execute more effectively as a separate division.”
“It’s an exciting time for QD Soleil to engage with larger companies best poised to fully exploit seminal IP, know-how and critically enabling technologies,” said Vijendra Sahi, VP and GM of the QD Soleil division. “We are particularly excited because we can utilize much of the technology base and materials now being launched in products by Nanosys.”
“The acquisition of QD Soleil would be an ingenious way, especially in this environment, to take a focused approached to innovation and R&D,” said Josh Wolfe, co-founder and Managing Partner of Lux Capital. “Furthermore, so significant is the QD Soleil patent portfolio and know how that it could be extremely valuable to any entity contemplating nanotechnology in solar today.”
For more information about Nanosys, visit the Company’s website at www.nanosysinc.com. For more information about QD Soleil, visit QD Soleil’s website at www.qdsoleil.com.
API Nanotronics Corp. (OTCBB: APIA) (”API” or the “Company”), a leading supplier of electronic components, systems and sub-systems, nano-optics and nanotechnology products to the aerospace, defense and communications sectors, today announced that its National Hybrid division(NHi) has expanded its sales and product development relationship with Israel based Sital Technology, the world leader in Mil-Std-1553 IP cores and products.
API’s NHi subsidiary, located in Ronkonkoma, New York, is a leader in the avionics industry in key MIL STD 1553 technologies and provides system engineers with new opportunities through Sital’s advanced Data Bus products. Customers in the U.S. can now purchase Sital’s products directly from NHi including IP Cores, Bus Testers, and DDC terminal drop-in replacements. These new products significantly broaden NHi’s product offerings, positioning the Company to provide customers complete solutions for their 1553 Data Bus needs. The companies also intend to co-develop next generation 1553 interface products, combining Sital’s industry leading IP core with NHi’s industry leading terminals, transceivers and transformers to develop the world’s most compact and powerful 1553 interface solutions.
Stephen B. Pudles, Chief Executive Officer of API Nanotronics Inc., said, “This partnership expands on our successful existing collaboration with Sital that resulted in our ARIES® product line. We are proud to represent Sital’s industry leading products in key markets and look forward to working together on future product offerings. This is a great opportunity for both companies.”
API’s National Hybrid division will be exhibiting at the coming Avionics show in San Diego on June 1 and 2.
About API Nanotronics Corp. (OTCBB: APIA)
API Nanotronics Corp., through its wholly owned subsidiaries API Electronics Inc., National Hybrid Inc., Filtran Group, TM Systems, Keytronics and API Nanofabrication Corporation, is engaged in the manufacture of electronic components and systems for the defense and communications industries. API is also developing a leadership position in the R&D and manufacture of nanotechnology and MEMS products. With a growing list of blue chip customers, including Honeywell/Allied Signal, General Dynamics, Lockheed Martin, and numerous other top technology-based firms around the world, API regularly ships products to clients in more than 34 countries. API owns state-of-the-art manufacturing and technology centers in New York, New Jersey and Ontario, Canada and has manufacturing capabilities in China and a distribution center in Britain. API Nanotronics trades on the OTC Bulletin Board under the symbol APIA. For further information, please visit the company website at www.apinanotronics.com.
About Sital Technology
Headquartered in Kfar-Saba, Israel, Sital Technology is an industry expert in MIL-STD-1553 design. The company develops intellectual property, components and testers for Mil-Std-1553 and other avionics applications and provides design and integration services. The principal staff are veterans of Israeli Air Force with in-depth understanding of avionics systems and its requirements. For more information about Sital visit www.sitaltech.com.
Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced it has received formal notification for the issuance of four patents in Mexico for its broad IP platform encompassing “Filtering Devices Incorporating Nanoparticles.” The patent coverage will include three main methods of associating nanoparticles with filter media: (1) having pellets of nanoparticles located adjacent to the filter media, (2) coating the filter media with a powder of nanoparticles, and (3) impregnating the nanoparticles into the filter media.
The Company already holds this broad patented protection in Australia, India, New Zealand, Russia, Singapore and Taiwan and has active applications encompassing 40+ countries around the world including the United States. “This expansion of protected intellectual property continues to increase the value of our overall portfolio and should build shareholder value. The strategic advantage of this specific coverage as it relates to potential licensee partnerships and nanotechnology enhanced filtration product manufacturing is quite promising,” said Thomas K. Allen, President and CEO, ANI.
In addition, ANI continues to focus on U.S. patent efforts tied to its NanoFense™ formulation, a proprietary antimicrobial nanoparticle filter “coating.” This technology development effort complements and bolsters all of the issued patent coverage for many air filtration applications in some of the most heavily populated regions of the world. “Our focused two-prong approach to building a valuable and synergistic IP portfolio will directly benefit potential licensees in all air filtration applications,” stated Mr. Allen.
About ANI
ANI is a marketer and developer of innovative nanotechnology-based air filtration products specifically targeted to eradicate bacteria, virus and fungi and is the owner of NEFT™ (Nanoparticle – Enhanced – Filtration – Technology), a broad platform with significant application potential in consumer and industrial market segments geared to reducing the transmission of infectious pathogens.
For further information about Applied Nanoscience Inc., please visit: www.appliednanoscience.com
Safe Harbor Statement
This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. ANI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today its new partner, NanoTherapies LLC, is utilizing calcium phosphate nanoparticles to detect and treat cancer. These particles are about 350 times smaller than a human cell while providing both a safe and effective way to transport drugs and imaging materials into diseased cells.
NanoTherapies has sole license and patent protection for the fundamental use of calcium phosphate nanoparticles in medical applications for the treatment and detection of blood cancers (all forms of leukemia). NanoTherapies has all rights to manufacturing technologies and intellectual property required to produce pharmaceutical quality drugs at the scale and yield needed for commercial viability.
Calcium phosphate is a major component of bones. NanoTherapies’ calcium phosphate NanoJackets clear the kidneys and liver without impact. They exit the body via the colon, and their chemical properties enable them to circulate in the bloodstream for prolonged periods yet dissolve in diseased cells, thereby releasing the drug. Metallic, silicon and carbon based nanoparticles cannot make the same claims regarding biocompatibility for humans nor do they have the chemical or physical properties that allow effective drug release in diseased cells.
Patient benefits from drugs jacketed with calcium phosphate nanoparticles are immense. Early lab studies show a ten-fold reduction in toxicity with a seven-fold increase in effectiveness for drugs delivered using NT’s technology. This means dramatically reduced side-effects owing to the severe toxicity of cancer drugs and increased effectiveness because the half-life of the drug is increased from minutes to hours. Most cancer drugs kill all the cells they contact and dissipate in less than thirty minutes. NT’s nanojackets encapsulate the drugs for up to thirty hours before being cleared from the body or until the nanoparticle enters a cancerous cell and release the drug. NT’s technology moves drug delivery strategies from carpet-bombing to smart-bombing with the corresponding dramatic decrease in collateral damage.
In the same way NT’s nanoparticles deliver drugs to cancerous cells they can also transport imaging dyes that fluoresce under near infrared light to reveal cancerous cells. Imaging cancer at the cellular level enables new methods of early detection of cancer as well as post-treatment and post-operative evaluation.
About Cancer Therapeutics, Inc.:
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words “estimate,” “anticipate,” “expect,” “believe,” and similar expressions are intended to be forward-looking statements.
Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary’s premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce completion of patient enrollment in the Company’s Phase II randomized, placebo-controlled, multi-center study to evaluate the safety, tolerability, immunogenicity, and antiretroviral activity of DermaVir Patch in treatment-naïve HIV-1-infected patients. The study is conducted in Hamburg, Germany with a total of thirty-six patients.
“We are very happy with completion of patient enrollment in this seminal trial because it allows us to conclude the immunization schedule in this year. This trial has a unique design to investigate DermaVir Patch as mono-immunotherapy in HIV-infected individuals who are not treated with antiretroviral drugs. We are very excited to learn how our immune therapeutic nanomedicine affects the immune system and disease of this patient population. With this trial we plan to demonstrate the safety and efficacy of DermaVir Patch as monotherapy administered every 6 weeks for the treatment of HIV,” commented Julianna Lisziewicz, CEO of Genetic Immunity.
This novel plasmid DNA-based nanomedicine vaccine candidate, DermaVir Patch, has been under development in the last ten years. Phase I trial showed preliminary safety and tolerability and induction of memory T-cell immunity in all HIV-1-infected individuals. DermaVir is based on a single plasmid DNA capable to express most HIV antigens and to form a virus-like particle (VLP+). Plasmid DNA is formulated with a polymer to mimic a pathogen. DermaVir enters into the body via the Langerhans cells of the skin and induces memory immune responses in the lymph nodes.
The primary outcome of this phase II study measures safety and tolerability of DermaVir Patch, while secondary outcome includes HIV-1 RNA measurements to assess the antiretroviral activity of the DermaVir Patch, changes in CD4+, CD8+ T-cell counts and HIV-specific immunogenicity during DermaVir Patch treatment.
The study randomized patients into one of 6 arms: Arm 1 patients will receive low dose DermaVir patch (0.2 mg DNA, n=9); Arm 2 patients will receive low dose placebo patch (n=3); Arm 3 patients will receive medium dose DermaVir patch (0.4 mg DNA, n=9); Arm 4 patients will receive medium dose placebo patch (n=3); Arm 5 patients will receive high dose DermaVir patch (0.8 mg DNA, n=9); Arm 6 patients will receive high dose placebo patch (n=3).
Immunization will be done on days 0, 42, 84, and 126. The total number of patches that a patient will receive throughout the study will be 8, 16, or 32 in the low, medium, and high dose arms, respectively. The patch sites for immunization are preferably the left or right upper back and left or right upper ventral thighs. The same skin sites might be used for all patch immunizations that last for 3 hours.
Patients will be on-study for 282 weeks. The immunizations will be administered over an 18-week period with an identical follow up schedule continuing until week 24; patients will be followed for an additional 24 weeks for additional safety and immunogenicity evaluations. An additional 234 weeks safety follow-up will be performed including chemistry and hematology assessments and physical examinations.
For more information please visit the Company’s official website at http://www.geneticimmunity.com
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary’s high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent “disruptive technologies.” We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call ‘disruptive technologies.’ For more information please visit our website at http://www.powerofthedream.com
NanoInk, Inc.®, a global leader in nanotechnology, is pleased to announce the appointment of renowned nanotechnology expert Deb Newberry to its NanoProfessor NanoScience Education Advisory Board. As a nuclear physicist with a background in chemical and mechanical engineering, Ms. Newberry will draw from her 23 years of experience in research and executive management to advise NanoInk in its efforts to work with government leaders, communities, and educational institutions to provide a hands-on curriculum in the science and art of nanotechnology. The NanoProfessor NanoScience Education Program will debut during the 2009-2010 academic year at Dakota County Technical College in Rosemount, Minn., where Ms. Newberry serves as director of the nanoscience technology program and newly funded NSF Regional Center for Nanotechnology Education, Nano-Link.
The National Science Foundation (NSF) has estimated that the world will require two million trained nanotechnologists by 2015, drawing attention to the immediate need for students to obtain practical, hands-on experience at the nanoscale level.
“As a teacher and life-long student of nanotechnology, I understand the importance of educating tomorrow’s industry leaders today,” said Deb Newberry. “The NanoProfessor Program will help prepare students for employment in the numerous industries where nanoscience applications are rapidly emerging. We are thrilled to be the first college to implement this program, and anticipate that it will be a driving force in creating a skilled workforce of nanotechnologists.”
The NanoProfessor Program leverages NanoInk’s state-of-the-art NLP 2000 Desktop Nanofabrication System, to provide students with the ability to quickly and easily build custom-engineered, nanoscale structures in a classroom setting.
Surrounding the NLP 2000 Desktop Nanofabrication System is an exciting nanoscience curriculum that is grounded in fundamental science and engineering concepts at the nanoscale level. Students will gain valuable and insightful experience through interdisciplinary focused, hands-on experiments and manufacturing via the state-of-the-art NLP 2000 System.
NanoInk is supporting the NanoProfessor Program with several initiatives focused on directing students into the programs of participating schools. Included in these initiatives are the NanoProfessor NanoScience Scholarship Program and marketing templates that participating schools can use in marketing their new or expanding nanoscience offerings to prospective students.
“Deb’s wealth of experience in the nanoscience field makes her an invaluable resource to our program, as we work to bring a hands-on nanotechnology curriculum to the classroom,” said Dean Hart, executive vice president for NanoInk. “She was instrumental in implementing the NanoProfessor Program at Dakota County Technical College, and will serve as a key component in the future growth of our program.”
Prior to Dakota County Technical College, Ms. Newberry worked in the corporate world for more than 23 years as a researcher and executive. She served as a space executive director for General Dynamics, a manufacturer of products for the aerospace, combat systems, marine systems and information systems industries.
Ms. Newberry also worked for NASA, where she studied radiation effects on micro and nanoscale satellites. She developed methodologies for analyzing and testing radiation on satellite systems, which has been employed on more than 14 spacecraft currently in orbit. She also held national leadership positions with the IEEE, a professional non-profit association for the advancement of technology, and the Aerospace Industries Association (AIA).
After leaving her corporate career in 2001, Ms. Newberry become a nanotechnology business consultant, and co-authored the book titled, “The Next Big Thing Is Really Small,” which describes how nanotechnology will revolutionize business.
Today, Ms. Newberry also serves as executive director of The NanoTechnology Group (TNTG), which supports the facilitation and development of nanoscale science education for grades pre-kindergarten through college. She is also chair of the board of directors and director of corporate relations for Project Universe, a Minnesota-based, non-profit corporation that produces space science media concepts for education and entertainment. Additionally, she serves on the editorial board for the Journal of Nano Education (JNE), and is a member of the following professional organizations: American Association for the Advancement of Science (AAAS); American Chemical Society (ACS); Foresight Institute; IEEE; Institute of Physics (IoP); LifeScience Alley®; Micro and Nanotechnology Commercialization Education Foundation (MANCEF); and the Minnesota High Tech Association (MHTA).
Ms. Newberry earned a master’s degree in nuclear physics from the University of North Dakota in Grand Forks, and has an extensive educational background in math, chemistry and mechanical engineering.
About NanoInk
NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and semiconductor industries. Using Dip Pen Nanolithography® (DPN®), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create nanoscale structures from a wide variety of materials. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has more than 140 patents and applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign. For more information on products and services offered by NanoInk, Inc., visit www.nanoink.net.
NanoInk, the NanoInk logo, Dip Pen Nanolithography and DPN are trademarks or registered trademarks of NanoInk, Inc.
Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), a nanotechnology-based filtration development company, today announced it has reached an agreement to collaborate on a surgical/protective mask application of the Company’s NEFT™ platform with a medical disposables company in the Asia Pacific region. Both companies intend to clearly define the commercial relationship required and to be implemented as part of the formal license agreement. The licensure of ANI’s broad IP platform encompassing “Filtering Devices Incorporating Nanoparticles,” will be combined with a separate license of ANI’s NanoFense™ formulation, a proprietary antimicrobial nanoparticle “coating” which can be applied to virtually any existing filter media.
“We are very excited at the potential of having an established leader and partner in this important market segment,” said Thomas K. Allen, President and CEO, ANI. “ANI has invested significant time and resources to develop and independently validate our air filter coating technology against a broad spectrum of virus, bacteria and fungi. We are confident that this prospective new partner has the established customer base and reputation to fully exploit the medical and general population markets for a product designed to protect people at a time when stopping the transmission of harmful disease is at the forefront. The product will likely be sold under their company name in many of the countries where ANI has issued patents covering our broad NEFT platform technology. It will likely retain the NanoFense brand and a reference to ANI. This allows us the opportunity to brand our technology and corporate name in key countries while the product benefits from their company’s strong name recognition. The name of the partner company will be released just prior to the release of the product for sale.”
Mr. Allen continued, “Additionally, we intend to provide them the NanoFense components premixed under our own label which they will then use to make their products. It is a very desirable arrangement in a market that provides Applied Nanoscience Inc. with substantial additional revenue opportunities.” NanoFense is currently patent pending in the United States.
About ANI
ANI is a marketer and developer of innovative nanotechnology-based air filtration products specifically targeted to eradicate bacteria, virus and fungi and is the owner of NEFT (Nanoparticle – Enhanced – Filtration – Technology), a broad platform with significant application potential in consumer and industrial market segments geared to reducing the transmission of infectious pathogens.
Safe Harbor Statement
This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. ANI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.
Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary’s premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
Genetic Immunity is pleased to announce completion of patient enrollment in the Company’s Phase II randomized, placebo-controlled trial designed to investigate whether therapeutic immunization during highly active antiretroviral therapy (HAART) induces elevations of HIV-specific T cell precursors with high proliferative capacity (PHPC) in HIV-1-infected individuals, and whether the quantity of PHPC correlates with the viral load set point following analytical treatment interruption (ATI). This second Phase II study is conducted at the IRCCS Policlinico S. Matteo in Pavia, Italy with a total of sixteen patients.
“We are extremely pleased to have enrolled all patients in this, our second Phase II trial aimed to prove the benefit of our immune amplification therapy. We now have two trials underway, in addition to a Phase I/II trial that is also nearing completion. I am confident this Italian trial, along with the one conducted in Hamburg, Germany will show substantial benefit for HIV infected patients. We look forward to receiving trial data once it is completed early in 2010,” commented Julianna Lisziewicz, CEO of Genetic Immunity.
Subjects in the study are randomized to receive either DermaVir Patch (8 subjects per cohort) or DermaVir Patch Placebo (8 subjects per cohort) every four weeks for three applications while receiving maximally suppressive HAART. HAART will be discontinued at Week 9 for an ATI period of 20 weeks.
Patients are on study for a total of 29 weeks (nine weeks of HAART followed by 20 weeks of ATI). Each subject’s DermaVir/Placebo application schedule is administered over an 8-week period (Day 0, 28, and 56). HAART is discontinued on Day 63 and is resumed on Day 203. Subsequently, individuals who do not meet HAART restarting criteria can elect not to restart therapy. After week 29 a safety and immunogenicity follow up evaluation is done every 3 months for an additional year for all the participants.
For more information please visit the Company’s official website at http://www.geneticimmunity.com
About Genetic Immunity
Genetic Immunity is a US/Hungarian biopharmaceutical company establishing leadership in Nanomedicines for immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for treating disease or repairing damaged tissues. By leveraging its proprietary immune amplification platform technology, the company aims to address new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines. These indications represent a significant unmet medical need and the potential for alternative treatment approaches.
About Power of the Dream Ventures
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary’s high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent “disruptive technologies.” We primarily focus on providing enabling solutions in the fields of environmental technologies, power generation and storage, software products and services, biotechnology, medical devices and what we call ‘disruptive technologies.’ For more information please visit our website at http://www.powerofthedream.com
|
|
